A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function.

ABSTRACT: Reduced kidney function (or kidney dysfunction) is commonly an exclusion criterion for randomised controlled trials (RCTs) in cancer. Consequently, high quality evidence for anticancer drug dosing in reduced kidney function is limited and no internationally agreed guidelines exist to inform prescribing decisions in this population. A methodology for guideline development was applied which did not require availability of RCTs but used critical appraisal of existing observational literature and group consensus. An international multidisciplinary working group (n = 38) established consensus recommendations in two parts to form the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD). The approach enabled virtual participation worldwide. In Part 1 we devel

SUBMITTER: Sandhu G 

PROVIDER: S-EPMC12034072 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature